- HNAB ABOUT TO RELEASE REVOLUTIONARY NDA - LUKEMIA



Hana Biosciences To Release Critical Flagship Product Trial Results At ASCO On May 20th, 2010

Many experts and inside sources are banking that the abstracts will be highly positive leading to it becoming one of the highest gaining small cap stocks this year

Dear Traders,

They are about to commence a rolling NDA submission for Marqibo after their meeting with FDA this quarter (pivotal phase 2 trial has been completed and if all goes as planned, the NDA will be submitted for treatment of 2nd relapse ALL in the 2nd half of 2010). Hana is greatly undervalued here, in our opinion. Late last year (2009), they were delisted from NASDAQ due to not meeting the minimum stockholders equity requirement. In December 2009, Hana announced results from their pivotal phase 2 study in ALL, the data was positive, but the stock took a tumble almost down to the 52wk low. The data is supposed to be updated at ASCO this June, which should provide a nice pop in the share price.
Marqibo is a version of an already used chemotherapeutic, but it is much more effective because it is built upon optisome nanoparticle technology (or "optiosmes"). Optisomes are a new generation of unique sphingomyelin/ cholesterol-based nanoparticles designed to encapsulate cell cycle-specific chemotherapeutics. Marqibo is being tested in multiple indications: front-line elderly PH(-) ALL, front-line aggresive NHL, pediatric cancers, and multiple myeloma.

But, Marqibo is not Hana's only product. They also have Alocrest (for the treatment of breast and lung cancer), Brakiva (for the treatment of SCLC and ovarian cancer), and Menandione Topical Lotion (for the treatment of skin rash associated w/ EGFR inhibitors. Examples of EGFR inhibitors are Tarceva®, Erbitux® and Vectibix®.). Please note, however, that these other three compounds are in early stages of testing (i.e phase 1 or 2).

Make sure to take a look at Hana's corporate presentation from January 11, 2010.

FDA Updates

Marqibo, vincristine sulfate liposomes injection, expects to submit NDA mid-2010 seeking accelerated approval for Marqibo based on phase 2 RALLY study results for treatment of adult acute lymphoblastic leukemia (ALL) ando ther data in solid tumors, planned pre-NDA meeting 2Q10, will present complete pivotal Phase 2 data at ASCO 06/07/2010

Menadione Topical Lotion - A topical compound for skin rash associated with Epidermal Growth Factor Receptor inhibitors such as Tarceva, Erbitux, and Vectibix, expects to provide intellectual property (IP) update mid-2010, present top-line proof-of-concept date mid-2010, also to begin phase 2 study 2H10.

On 12/7/09, HNAB.OB announcd data from its pivotal phase 2 RALLY clinical trial for Marqibo (vincristine sulfate liposomes injection) for treatment of adult acute lymphoblastic leukemia (ALL) in second relapse. The analysis of the first 56 evaluable subjects demonstrated an overall response in 36% of the subjects and a complete hematologic recovery (CRi) in 21% of subjects. The estimated median overall survival in complete responders was 7.3 months. 50% of the complete responders were able to receive potentially life-saving stem cell transplant. 50% of the complete responders had remission durations longer than the duration of their prior remission. In addition, Marqibo was generally well-tolerated with a low incidence of early death. Based on the RALLY trial data, other published Marqibo data in adult ALL, and supportive data in lymphomas and solid tumors, HNAB.OB plans to submit a New Drug Application (NDA) seeking accelerated approval for Marqibo in 2010. In addition, final data on all 65 subjects enrolled and dosed in phase 2 RALLY trial willbe presented in 2010.

If all goes as it should, Hana could be one of the biggest "BioShockers" of the year.

- HNAB SUBMITTING REOVLUTIONARY LUKEMIA NDA -



Hana Biosciences To Release Critical Flagship Product Trial Results At ASCO On May 20th, 2010

Many experts and inside sources are banking that the abstracts will be highly positive leading to it becoming one of the highest gaining small cap stocks this year

Dear Traders,

They are about to commence a rolling NDA submission for Marqibo after their meeting with FDA this quarter (pivotal phase 2 trial has been completed and if all goes as planned, the NDA will be submitted for treatment of 2nd relapse ALL in the 2nd half of 2010). Hana is greatly undervalued here, in our opinion. Late last year (2009), they were delisted from NASDAQ due to not meeting the minimum stockholders equity requirement. In December 2009, Hana announced results from their pivotal phase 2 study in ALL, the data was positive, but the stock took a tumble almost down to the 52wk low. The data is supposed to be updated at ASCO this June, which should provide a nice pop in the share price.
Marqibo is a version of an already used chemotherapeutic, but it is much more effective because it is built upon optisome nanoparticle technology (or "optiosmes"). Optisomes are a new generation of unique sphingomyelin/ cholesterol-based nanoparticles designed to encapsulate cell cycle-specific chemotherapeutics. Marqibo is being tested in multiple indications: front-line elderly PH(-) ALL, front-line aggresive NHL, pediatric cancers, and multiple myeloma.

But, Marqibo is not Hana's only product. They also have Alocrest (for the treatment of breast and lung cancer), Brakiva (for the treatment of SCLC and ovarian cancer), and Menandione Topical Lotion (for the treatment of skin rash associated w/ EGFR inhibitors. Examples of EGFR inhibitors are Tarceva®, Erbitux® and Vectibix®.). Please note, however, that these other three compounds are in early stages of testing (i.e phase 1 or 2).

Make sure to take a look at Hana's corporate presentation from January 11, 2010.

FDA Updates

Marqibo, vincristine sulfate liposomes injection, expects to submit NDA mid-2010 seeking accelerated approval for Marqibo based on phase 2 RALLY study results for treatment of adult acute lymphoblastic leukemia (ALL) ando ther data in solid tumors, planned pre-NDA meeting 2Q10, will present complete pivotal Phase 2 data at ASCO 06/07/2010

Menadione Topical Lotion - A topical compound for skin rash associated with Epidermal Growth Factor Receptor inhibitors such as Tarceva, Erbitux, and Vectibix, expects to provide intellectual property (IP) update mid-2010, present top-line proof-of-concept date mid-2010, also to begin phase 2 study 2H10.

On 12/7/09, HNAB.OB announcd data from its pivotal phase 2 RALLY clinical trial for Marqibo (vincristine sulfate liposomes injection) for treatment of adult acute lymphoblastic leukemia (ALL) in second relapse. The analysis of the first 56 evaluable subjects demonstrated an overall response in 36% of the subjects and a complete hematologic recovery (CRi) in 21% of subjects. The estimated median overall survival in complete responders was 7.3 months. 50% of the complete responders were able to receive potentially life-saving stem cell transplant. 50% of the complete responders had remission durations longer than the duration of their prior remission. In addition, Marqibo was generally well-tolerated with a low incidence of early death. Based on the RALLY trial data, other published Marqibo data in adult ALL, and supportive data in lymphomas and solid tumors, HNAB.OB plans to submit a New Drug Application (NDA) seeking accelerated approval for Marqibo in 2010. In addition, final data on all 65 subjects enrolled and dosed in phase 2 RALLY trial willbe presented in 2010.

If all goes as it should, Hana could be one of the biggest "BioShockers" of the year.

HNAB - THE NEXT BIG SMALLCAP BIOTECH PLAY - LUKEMIA NDA



Hana Biosciences To Release Critical Flagship Product Trial Results At ASCO On May 20th, 2010

Many experts and inside sources are banking that the abstracts will be highly positive leading to it becoming one of the highest gaining small cap stocks this year

Dear Traders,

They are about to commence a rolling NDA submission for Marqibo after their meeting with FDA this quarter (pivotal phase 2 trial has been completed and if all goes as planned, the NDA will be submitted for treatment of 2nd relapse ALL in the 2nd half of 2010). Hana is greatly undervalued here, in our opinion. Late last year (2009), they were delisted from NASDAQ due to not meeting the minimum stockholders equity requirement. In December 2009, Hana announced results from their pivotal phase 2 study in ALL, the data was positive, but the stock took a tumble almost down to the 52wk low. The data is supposed to be updated at ASCO this June, which should provide a nice pop in the share price.
Marqibo is a version of an already used chemotherapeutic, but it is much more effective because it is built upon optisome nanoparticle technology (or "optiosmes"). Optisomes are a new generation of unique sphingomyelin/ cholesterol-based nanoparticles designed to encapsulate cell cycle-specific chemotherapeutics. Marqibo is being tested in multiple indications: front-line elderly PH(-) ALL, front-line aggresive NHL, pediatric cancers, and multiple myeloma.

But, Marqibo is not Hana's only product. They also have Alocrest (for the treatment of breast and lung cancer), Brakiva (for the treatment of SCLC and ovarian cancer), and Menandione Topical Lotion (for the treatment of skin rash associated w/ EGFR inhibitors. Examples of EGFR inhibitors are Tarceva®, Erbitux® and Vectibix®.). Please note, however, that these other three compounds are in early stages of testing (i.e phase 1 or 2).

Make sure to take a look at Hana's corporate presentation from January 11, 2010.

FDA Updates

Marqibo, vincristine sulfate liposomes injection, expects to submit NDA mid-2010 seeking accelerated approval for Marqibo based on phase 2 RALLY study results for treatment of adult acute lymphoblastic leukemia (ALL) ando ther data in solid tumors, planned pre-NDA meeting 2Q10, will present complete pivotal Phase 2 data at ASCO 06/07/2010

Menadione Topical Lotion - A topical compound for skin rash associated with Epidermal Growth Factor Receptor inhibitors such as Tarceva, Erbitux, and Vectibix, expects to provide intellectual property (IP) update mid-2010, present top-line proof-of-concept date mid-2010, also to begin phase 2 study 2H10.

On 12/7/09, HNAB.OB announcd data from its pivotal phase 2 RALLY clinical trial for Marqibo (vincristine sulfate liposomes injection) for treatment of adult acute lymphoblastic leukemia (ALL) in second relapse. The analysis of the first 56 evaluable subjects demonstrated an overall response in 36% of the subjects and a complete hematologic recovery (CRi) in 21% of subjects. The estimated median overall survival in complete responders was 7.3 months. 50% of the complete responders were able to receive potentially life-saving stem cell transplant. 50% of the complete responders had remission durations longer than the duration of their prior remission. In addition, Marqibo was generally well-tolerated with a low incidence of early death. Based on the RALLY trial data, other published Marqibo data in adult ALL, and supportive data in lymphomas and solid tumors, HNAB.OB plans to submit a New Drug Application (NDA) seeking accelerated approval for Marqibo in 2010. In addition, final data on all 65 subjects enrolled and dosed in phase 2 RALLY trial willbe presented in 2010.

If all goes as it should, Hana could be one of the biggest "BioShockers" of the year.



check it out!

HNAB - THE NEXT BIG BIOTECH SMALL CAP GAINER - info

Hana Biosciences To Release Critical Flagship Product Trial Results At ASCO On May 20th, 2010

Many experts and inside sources are banking that the abstracts will be highly positive leading to it becoming one of the highest gaining small cap stocks this year

Dear Traders,

They are about to commence a rolling NDA submission for Marqibo after their meeting with FDA this quarter (pivotal phase 2 trial has been completed and if all goes as planned, the NDA will be submitted for treatment of 2nd relapse ALL in the 2nd half of 2010). Hana is greatly undervalued here, in our opinion. Late last year (2009), they were delisted from NASDAQ due to not meeting the minimum stockholders equity requirement. In December 2009, Hana announced results from their pivotal phase 2 study in ALL, the data was positive, but the stock took a tumble almost down to the 52wk low. The data is supposed to be updated at ASCO this June, which should provide a nice pop in the share price.
Marqibo is a version of an already used chemotherapeutic, but it is much more effective because it is built upon optisome nanoparticle technology (or "optiosmes"). Optisomes are a new generation of unique sphingomyelin/ cholesterol-based nanoparticles designed to encapsulate cell cycle-specific chemotherapeutics. Marqibo is being tested in multiple indications: front-line elderly PH(-) ALL, front-line aggresive NHL, pediatric cancers, and multiple myeloma.

But, Marqibo is not Hana's only product. They also have Alocrest (for the treatment of breast and lung cancer), Brakiva (for the treatment of SCLC and ovarian cancer), and Menandione Topical Lotion (for the treatment of skin rash associated w/ EGFR inhibitors. Examples of EGFR inhibitors are Tarceva®, Erbitux® and Vectibix®.). Please note, however, that these other three compounds are in early stages of testing (i.e phase 1 or 2).

Make sure to take a look at Hana's corporate presentation from January 11, 2010.

FDA Updates

Marqibo, vincristine sulfate liposomes injection, expects to submit NDA mid-2010 seeking accelerated approval for Marqibo based on phase 2 RALLY study results for treatment of adult acute lymphoblastic leukemia (ALL) ando ther data in solid tumors, planned pre-NDA meeting 2Q10, will present complete pivotal Phase 2 data at ASCO 06/07/2010

Menadione Topical Lotion - A topical compound for skin rash associated with Epidermal Growth Factor Receptor inhibitors such as Tarceva, Erbitux, and Vectibix, expects to provide intellectual property (IP) update mid-2010, present top-line proof-of-concept date mid-2010, also to begin phase 2 study 2H10.

On 12/7/09, HNAB.OB announcd data from its pivotal phase 2 RALLY clinical trial for Marqibo (vincristine sulfate liposomes injection) for treatment of adult acute lymphoblastic leukemia (ALL) in second relapse. The analysis of the first 56 evaluable subjects demonstrated an overall response in 36% of the subjects and a complete hematologic recovery (CRi) in 21% of subjects. The estimated median overall survival in complete responders was 7.3 months. 50% of the complete responders were able to receive potentially life-saving stem cell transplant. 50% of the complete responders had remission durations longer than the duration of their prior remission. In addition, Marqibo was generally well-tolerated with a low incidence of early death. Based on the RALLY trial data, other published Marqibo data in adult ALL, and supportive data in lymphomas and solid tumors, HNAB.OB plans to submit a New Drug Application (NDA) seeking accelerated approval for Marqibo in 2010. In addition, final data on all 65 subjects enrolled and dosed in phase 2 RALLY trial willbe presented in 2010.

If all goes as it should, Hana could be one of the biggest "BioShockers" of the year.

Discovery Laboratories: Small Biotech Company With Multiple Prime Time Catalysts


Amidst buyout / partnership rumours from the top drug makers in the world, of the likes including Johnson & Johnson (NYSE:JNJ), Merck & Co. (NYSE:MRK) and Pfizer (NYSE:PFE), Discovery Laboratories is stepping up to the plate with some major upcoming company developments that could make this the next small cap home run play. Among the upcoming binary events: completion of BAT during May as the last step for FDA resubmission on its flagship product, phase 2 results for Acute Respiratory Failure in June, initiation of phase 2a trial for Cystic Fibrosis in 3Q10, and FDA submission of the flagship product, Surfaxin in the treatment of ARDS, during 1Q11. Make no mistake about it, there is serious room for growth as this 70M market cap company and Surfaxin is tapping into a $1.8 billion dollar market opportunity for Acute Respiratory Distress Syndrome, of which currently there are no drugs approved for treatment. What makes this story even more compelling is that Discovery has met and received response letters from the FDA a total of three times, all with minor requirements that have since been met and completed. As a well-capitalized company paired with strong fundamental and technical chart breakout potential, it is undeniable that its re-emergence as healthy NASDAQ listed company is right around the corner.

talk about prime time potential...imho big play next week

http://www.themarketfinancial.com/discovery-laboratories-small-biotech-company-with-multiple-prime-time-catalysts/2544

Discovery Laboratories: Small Biotech Company With Multiple Prime Time Catalysts


Amidst buyout / partnership rumours from the top drug makers in the world, of the likes including Johnson & Johnson (NYSE:JNJ), Merck & Co. (NYSE:MRK) and Pfizer (NYSE:PFE), Discovery Laboratories is stepping up to the plate with some major upcoming company developments that could make this the next small cap home run play. Among the upcoming binary events: completion of BAT during May as the last step for FDA resubmission on its flagship product, phase 2 results for Acute Respiratory Failure in June, initiation of phase 2a trial for Cystic Fibrosis in 3Q10, and FDA submission of the flagship product, Surfaxin in the treatment of ARDS, during 1Q11. Make no mistake about it, there is serious room for growth as this 70M market cap company and Surfaxin is tapping into a $1.8 billion dollar market opportunity for Acute Respiratory Distress Syndrome, of which currently there are no drugs approved for treatment. What makes this story even more compelling is that Discovery has met and received response letters from the FDA a total of three times, all with minor requirements that have since been met and completed. As a well-capitalized company paired with strong fundamental and technical chart breakout potential, it is undeniable that its re-emergence as healthy NASDAQ listed company is right around the corner.

going to be crazy play next weeek imho....

http://www.themarketfinancial.com/discovery-laboratories-small-biotech-company-with-multiple-prime-time-catalysts/2544

Discovery Laboratories: Small Biotech Company With Multiple Prime Time Catalysts


Amidst buyout / partnership rumours from the top drug makers in the world, of the likes including Johnson & Johnson (NYSE:JNJ), Merck & Co. (NYSE:MRK) and Pfizer (NYSE:PFE), Discovery Laboratories is stepping up to the plate with some major upcoming company developments that could make this the next small cap home run play. Among the upcoming binary events: completion of BAT during May as the last step for FDA resubmission on its flagship product, phase 2 results for Acute Respiratory Failure in June, initiation of phase 2a trial for Cystic Fibrosis in 3Q10, and FDA submission of the flagship product, Surfaxin in the treatment of ARDS, during 1Q11. Make no mistake about it, there is serious room for growth as this 70M market cap company and Surfaxin is tapping into a $1.8 billion dollar market opportunity for Acute Respiratory Distress Syndrome, of which currently there are no drugs approved for treatment. What makes this story even more compelling is that Discovery has met and received response letters from the FDA a total of three times, all with minor requirements that have since been met and completed. As a well-capitalized company paired with strong fundamental and technical chart breakout potential, it is undeniable that its re-emergence as healthy NASDAQ listed company is right around the corner.

Check out the full report! BIIIGGGG play

http://www.themarketfinancial.com/discovery-laboratories-small-biotech-company-with-multiple-prime-time-catalysts/2544

Discovery Laboratories: Small Biotech Company With Multiple Prime Time Catalysts


Amidst buyout / partnership rumours from the top drug makers in the world, of the likes including Johnson & Johnson (NYSE:JNJ), Merck & Co. (NYSE:MRK) and Pfizer (NYSE:PFE), Discovery Laboratories is stepping up to the plate with some major upcoming company developments that could make this the next small cap home run play. Among the upcoming binary events: completion of BAT during May as the last step for FDA resubmission on its flagship product, phase 2 results for Acute Respiratory Failure in June, initiation of phase 2a trial for Cystic Fibrosis in 3Q10, and FDA submission of the flagship product, Surfaxin in the treatment of ARDS, during 1Q11. Make no mistake about it, there is serious room for growth as this 70M market cap company and Surfaxin is tapping into a $1.8 billion dollar market opportunity for Acute Respiratory Distress Syndrome, of which currently there are no drugs approved for treatment. What makes this story even more compelling is that Discovery has met and received response letters from the FDA a total of three times, all with minor requirements that have since been met and completed. As a well-capitalized company paired with strong fundamental and technical chart breakout potential, it is undeniable that its re-emergence as healthy NASDAQ listed company is right around the corner.



http://www.themarketfinancial.com/discovery-laboratories-small-biotech-company-with-multiple-prime-time-catalysts/2544

Must Read On AEZS, Prime Time Cancer Company In The Making

http://www.themarketfinancial.com/aeterna-zentaris-uncovering-the-next-dominant-cancer-company/2489

TheMarketFinancial.com is in on the action, check out their latest post here:

http://www.themarketfinancial.com/arrayit-an-unparalleled-ovarian-cancer-market-opportunity/2438

DNDN's new twin is AEZS

AEZS = THE NEW DNDN...CHECK OUT ITS HUGE ONCOLOGICAL PIPELINE!!!




AEterna Zentaris Inc.
(NASDAQ:AEZS)

The company is pending a large inflow of news items for its extensive clinical pipeline, and sources tell us the news is edging towards the positive end. Here is an updated timeline of what to expect:

This may near $3 soon and reach as high as $20-$50 by next year or two. A current market cap of only $80M leaves the door open for plenty of shareholder value opportunities. They will also be attending the ASCO conference in June, increasing transparency and most likely the buying pressure as high profile sources and Wall Street continue to discover this undervalued company.

1) Bone Marrow Cancer: Developing perifosine, the first-in-class oral AKT inhibitor. A Phase III study, the last stage before commercialization, is currently being conducted in the United States for myeloma, a form of bone marrow cancer. Perifosine has been granted a fast-track designation and orphan-drug designation by the FDA.

2) Colon cancer: Keryx is about to start a Phase III study with this same compound in metastatic colon cancer

3) Endometrial cancer and Ovarian cancer: AEZS-108. Conducting a Phase II study in Europe for endometrial cancer and ovarian cancer. We expect to disclose the final results later this year.

4) Bladder cancer, pancreatic cancer and prostate cancer: We also look to possibly conduct other clinical studies in bladder cancer, and pancreatic cancer and refractory prostate cancer

5) In vitro fertilization: In endocrinology we already have a marketed product for in vitro fertilization under the brand name Cetrotide(c). It is being marketed worldwide by Merck Serono, except in Japan, where it's marketed by Nippon Kayaku and Shionogi.

6) Growth hormone deficiency: Our lead endocrinology compound in late-stage development is AEZS-130, which is in Phase III as a diagnostic test for growth hormone deficiency . We also have an orphan-drug designation for this drug in the United States.

7) Currently in discussions with the FDA in order to find the best way to finalize this study for AEZS-130 and file for an approval at the end of this year

8) Children diagnostic test: We are also aiming for diagnostic use of AEZS-130 in children. And the unique selling point of this project is that this will be the first oral diagnostic test.

9) Treat cachexia: AEZS-130 has shown to stimulate appetite and therefore could be used to treat cachexia, a condition which results in a severe reduction of muscle mass and weight loss in patients suffering from conditions such as chronic obstructive pulmonary disease, AIDS and certain cancers.

10) At the pre-clinical development stage, we have some very unique molecules which are dual inhibitors of PI3K and Erk, two hot targets in oncology at present, and also a selective Erk inhibitor.

11) Some of these early-stage projects as well as our more advanced ones will be the object of presentations at major conferences throughout 2010, such as the American Society of Clinical Oncology, ASCO, and American Association of Cancer Research meetings.

Can AEZS be the next DNDN?

AEZS = THE NEW DNDN...CHECK OUT ITS HUGE ONCOLOGICAL PIPELINE!!!




AEterna Zentaris Inc.
(NASDAQ:AEZS)

The company is pending a large inflow of news items for its extensive clinical pipeline, and sources tell us the news is edging towards the positive end. Here is an updated timeline of what to expect:

This may near $3 soon and reach as high as $20-$50 by next year or two. A current market cap of only $80M leaves the door open for plenty of shareholder value opportunities. They will also be attending the ASCO conference in June, increasing transparency and most likely the buying pressure as high profile sources and Wall Street continue to discover this undervalued company.

1) Bone Marrow Cancer: Developing perifosine, the first-in-class oral AKT inhibitor. A Phase III study, the last stage before commercialization, is currently being conducted in the United States for myeloma, a form of bone marrow cancer. Perifosine has been granted a fast-track designation and orphan-drug designation by the FDA.

2) Colon cancer: Keryx is about to start a Phase III study with this same compound in metastatic colon cancer

3) Endometrial cancer and Ovarian cancer: AEZS-108. Conducting a Phase II study in Europe for endometrial cancer and ovarian cancer. We expect to disclose the final results later this year.

4) Bladder cancer, pancreatic cancer and prostate cancer: We also look to possibly conduct other clinical studies in bladder cancer, and pancreatic cancer and refractory prostate cancer

5) In vitro fertilization: In endocrinology we already have a marketed product for in vitro fertilization under the brand name Cetrotide(c). It is being marketed worldwide by Merck Serono, except in Japan, where it's marketed by Nippon Kayaku and Shionogi.

6) Growth hormone deficiency: Our lead endocrinology compound in late-stage development is AEZS-130, which is in Phase III as a diagnostic test for growth hormone deficiency . We also have an orphan-drug designation for this drug in the United States.

7) Currently in discussions with the FDA in order to find the best way to finalize this study for AEZS-130 and file for an approval at the end of this year

8) Children diagnostic test: We are also aiming for diagnostic use of AEZS-130 in children. And the unique selling point of this project is that this will be the first oral diagnostic test.

9) Treat cachexia: AEZS-130 has shown to stimulate appetite and therefore could be used to treat cachexia, a condition which results in a severe reduction of muscle mass and weight loss in patients suffering from conditions such as chronic obstructive pulmonary disease, AIDS and certain cancers.

10) At the pre-clinical development stage, we have some very unique molecules which are dual inhibitors of PI3K and Erk, two hot targets in oncology at present, and also a selective Erk inhibitor.

11) Some of these early-stage projects as well as our more advanced ones will be the object of presentations at major conferences throughout 2010, such as the American Society of Clinical Oncology, ASCO, and American Association of Cancer Research meetings.

Anyone here looking for the next DNDN?

AEZS = THE NEW DNDN...CHECK OUT ITS HUGE ONCOLOGICAL PIPELINE!!!




AEterna Zentaris Inc.
(NASDAQ:AEZS)

The company is pending a large inflow of news items for its extensive clinical pipeline, and sources tell us the news is edging towards the positive end. Here is an updated timeline of what to expect:

This may near $3 soon and reach as high as $20-$50 by next year or two. A current market cap of only $80M leaves the door open for plenty of shareholder value opportunities. They will also be attending the ASCO conference in June, increasing transparency and most likely the buying pressure as high profile sources and Wall Street continue to discover this undervalued company.

1) Bone Marrow Cancer: Developing perifosine, the first-in-class oral AKT inhibitor. A Phase III study, the last stage before commercialization, is currently being conducted in the United States for myeloma, a form of bone marrow cancer. Perifosine has been granted a fast-track designation and orphan-drug designation by the FDA.

2) Colon cancer: Keryx is about to start a Phase III study with this same compound in metastatic colon cancer

3) Endometrial cancer and Ovarian cancer: AEZS-108. Conducting a Phase II study in Europe for endometrial cancer and ovarian cancer. We expect to disclose the final results later this year.

4) Bladder cancer, pancreatic cancer and prostate cancer: We also look to possibly conduct other clinical studies in bladder cancer, and pancreatic cancer and refractory prostate cancer

5) In vitro fertilization: In endocrinology we already have a marketed product for in vitro fertilization under the brand name Cetrotide(c). It is being marketed worldwide by Merck Serono, except in Japan, where it's marketed by Nippon Kayaku and Shionogi.

6) Growth hormone deficiency: Our lead endocrinology compound in late-stage development is AEZS-130, which is in Phase III as a diagnostic test for growth hormone deficiency . We also have an orphan-drug designation for this drug in the United States.

7) Currently in discussions with the FDA in order to find the best way to finalize this study for AEZS-130 and file for an approval at the end of this year

8) Children diagnostic test: We are also aiming for diagnostic use of AEZS-130 in children. And the unique selling point of this project is that this will be the first oral diagnostic test.

9) Treat cachexia: AEZS-130 has shown to stimulate appetite and therefore could be used to treat cachexia, a condition which results in a severe reduction of muscle mass and weight loss in patients suffering from conditions such as chronic obstructive pulmonary disease, AIDS and certain cancers.

10) At the pre-clinical development stage, we have some very unique molecules which are dual inhibitors of PI3K and Erk, two hot targets in oncology at present, and also a selective Erk inhibitor.

11) Some of these early-stage projects as well as our more advanced ones will be the object of presentations at major conferences throughout 2010, such as the American Society of Clinical Oncology, ASCO, and American Association of Cancer Research meetings.

Oh and he also confirmed that there is major pending news FROM THE COMPANY itself next week. Stay patient, be a smart investor.

Just spoke with Michael from TheMarketFianncial, and he said to tell all of you that he had only the best of intentions, and that the compensation finished 3 months ago. He actually bought more shares on the open market himself, including adding to his position today.

It's easy to put the blame finger on those in the spotlight rather than the Market Makers such as Knight Capital and DOMS.

AspenBio Pharma Days Away From Announcing Pivotal Study Results For First Ever Appendicitis Blood Diagnostics Test

Investors are banking that results are positive, phase II showcased a 98% sensitivity, much higher than required for 510(k) medical device approvals


Dear Traders,

We are currently working on a report which should be out by tonight on a company which truly could become the next game changer within the biotech stratosphere.We've all been waiting for the next HGSI / DNDN, and it seems that AspenBio Pharma (APPY) has quietly tiptoed into the FDA scene.

Barely getting noticed on its impending phase III results for what could be one of the biggest medical breakthroughs of 2010, a medical blood diagnostics test for appendicitis, a condition that affects nearly 10% of North Americans and has a potential $1B market, whereby (APPY) would have no competition in, thus creating a monopoly similar to say Microsoft with Windows.

FDA News


On 2/9/10, APPY reported conclusions from tis pre-planned independent, interim analysis of an ongoing supplemental trial of AppyScore, the first blood-based test designed to aid in the evaluation of patients suspected of having acute appendicitis, and outline the next steps for its AppyScore 510(k) ifling with the FDA. Based on this, approximately 800 patients were enrolled on 3/23/10. APPY estimates that May 4th to 18th the data analysis will be available to include in its pending 510(k) submission to the FDA which will also come in 2Q10.

Highly Positive Results in Phase II

In September 2007, we announced the results of a 471 patient study conducted at multiple hospital sites under appropriate Institutional Review Board Approvals and patient consent. Out of 471 patients, 100 were normal presumably healthy control donors. The 100 normal AppyScore control individuals were used to characterize and confirm the blood level of the proprietary biomarker used in AppyScore in normal healthy individuals. The remaining 371 were patients who entered to the emergency rooms with abdominal pain, with appendicitis as a possible diagnosis. A total of 97 of 311 or 31% of patients had pathology-confirmed appendicitis in the study. AppyScore was able to correctly identify 95 of 97 patients with pathology-confirmed appendicitis. This exceptionally high sensitivity level of 98% for detecting the actual disease condition is considered statistically significant (95% CI = 93% to 99.9%). In addition, the combination of using the data from AppyScore in conjunction with a CT scan resulted in a specificity of 99% (95% CI = 97% to 99.9%).

AspenBio Pharma Days Away From Announcing Pivotal Study Results For First Ever Appendicitis Blood Diagnostics Test

Investors are banking that results are positive, phase II showcased a 98% sensitivity, much higher than required for 510(k) medical device approvals


Dear Traders,

We are currently working on a report which should be out by tonight on a company which truly could become the next game changer within the biotech stratosphere.We've all been waiting for the next HGSI / DNDN, and it seems that AspenBio Pharma (APPY) has quietly tiptoed into the FDA scene.

Barely getting noticed on its impending phase III results for what could be one of the biggest medical breakthroughs of 2010, a medical blood diagnostics test for appendicitis, a condition that affects nearly 10% of North Americans and has a potential $1B market, whereby (APPY) would have no competition in, thus creating a monopoly similar to say Microsoft with Windows.

FDA News


On 2/9/10, APPY reported conclusions from tis pre-planned independent, interim analysis of an ongoing supplemental trial of AppyScore, the first blood-based test designed to aid in the evaluation of patients suspected of having acute appendicitis, and outline the next steps for its AppyScore 510(k) ifling with the FDA. Based on this, approximately 800 patients were enrolled on 3/23/10. APPY estimates that May 4th to 18th the data analysis will be available to include in its pending 510(k) submission to the FDA which will also come in 2Q10.

Highly Positive Results in Phase II

In September 2007, we announced the results of a 471 patient study conducted at multiple hospital sites under appropriate Institutional Review Board Approvals and patient consent. Out of 471 patients, 100 were normal presumably healthy control donors. The 100 normal AppyScore control individuals were used to characterize and confirm the blood level of the proprietary biomarker used in AppyScore in normal healthy individuals. The remaining 371 were patients who entered to the emergency rooms with abdominal pain, with appendicitis as a possible diagnosis. A total of 97 of 311 or 31% of patients had pathology-confirmed appendicitis in the study. AppyScore was able to correctly identify 95 of 97 patients with pathology-confirmed appendicitis. This exceptionally high sensitivity level of 98% for detecting the actual disease condition is considered statistically significant (95% CI = 93% to 99.9%). In addition, the combination of using the data from AppyScore in conjunction with a CT scan resulted in a specificity of 99% (95% CI = 97% to 99.9%).

NITE NOW AT 0.23/0.25.... hes making a killing, he wants this to EXPLODE!

AMAZING... NITE IS PUSHING UP THE BIDS... hes on our side for once?!?!?? been watching him push up bid n ask all day.... wtf lol hes a PVHOER!

if we get PRs next week... KABBOOOOOM 0.45 here we come and beyond.

We're going to tear through that 0.45 high this time around. Book it.

Search for "Financial Market" on google... out of 70 million plus sites, theirs ranks 5th. Above bloomberg / wall street journal and more... insane.

what does SS? mean?

Partnership / contract news coming.... start telling your friends, get the board going.... lets get it rolling.

THIS IS THE NEWS THATS COMING


1. 8k, Circle K, and the logistics of the roll out

2. Planned financing for the Circle K project

3. Institutional Financing progress

4. Signed contract in gaming market; plans and activities

5. Launch of LA grocery store 3D network; advertisers pending

6. Ready to announce signed contact with NY agency

7. Digital Signage Expo in Las Vegas this week

8. Upcoming Intel Conference speaking engagement

Laughs at all of you sitting on the sidelines talking trash on the monster GETA

Closing @ 0.09 is the 50 DMA, means tomorrow we open higher, and with any volume we could test the 200 DMA of $0.31 rather quickly.

http://www.themarketfinancial.com/new-year-new-genta-new-found-glory-otcgeta/2020

ENOUGH SAID

New Google News item:


Emerging Pattern of Bullish Breakout

What is LTF?

100k trades explained

Since this stock's price is too low, no one will make a trade for negative dollars, so anything >0 goes, thus 100k share blocks apply and essentially mean the same thing as 100 which is used for higher priced stocks.

Penny traders believe that Market Makers (MM) will "signal" moves in advance buy using small amounts of buys or sells as "signals". The "signals" are such a small amount of shares (worth no more than 5 or 10 dollars) that no trader would have paid a commission that costs more than the amount of shares bought. The "signals" are from one MM to another.




* 100 I need shares.
* 200 I need shares badly,but do not take the stock down.
* 300 Take the price down so I can load shares
* 400 Keep trading it sideways.
* 500 Gap the stock. This gap can be either up or down, depending on the direction of the 500 signal.

Patience our time will come.

WHAT NEWS IS PENDING HERE?

Neither, its information already available its just simply not viral yet. Stay tunned.

Where is the news on OTCBB?

WOW what is this gem we have over here?

FORBES TALKS CPRK http://www.forbes.com/feeds/prnewswire/2010/03/04/prnewswire201003041750PR_NEWS_USPR_____PH65514.html

Ospreyeye, how stupid can you be. Read the full article and disclosure at the bottom.


Disclosure: Long SSEV
TheMarketFinancial is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated.

UPDATED CHART ANALYSIS BY TheMarketFinancial

NEW REPORT BY TMF:

http://www.themarketfinancial.com/copper-king-moves-towards-transparency-and-discusses-upgrades-and-restart-of-mill/1787